Maynard Group’s Preclinical Findings Bring Whooping Cough Treatment Closer to Human Trials
Texas ChE researchers recently published preclinical test results showing the use of antibodies in mice and baboons was successful in providing short-term immunity and an accelerated recovery from pertussis, also known as whooping cough. The findings, which were published in a paper on Dec. 2 in Science Translational Medicine, will help advance the treatment to human trials.
The team, lead by Associate Professor Jennifer Maynard, has been working with Synthetic Biologics Inc. to develop two antibodies as a new anti-pertussis therapeutic injection to potentially treat or prevent the disease. Pertussis, or whooping cough, is a highly contagious respiratory tract infection that causes painful fits of coughing and life-threatening symptoms in infants. It affects millions worldwide and results in an estimated 200,000 child deaths every year.
According to the Centers for Disease Control and Prevention, more than 16 million pertussis cases occur annually, and the disease continues to be a major cause of infant death in developing nations. In the United States, childhood vaccinations largely prevent the disease, but there still has been an increase in incidence during the past 20 years, including several outbreaks in recent years. Antibiotics are frequently ineffective in severe pertussis, and there is no specific therapeutic to treat pertussis in these infants or prevent it in vulnerable infants too young to be vaccinated — but now there may be hope for the future.
Maynard is collaborating with Dr. Michael Kaleko, senior vice president of research and development for Synthetic Biologics, a co-author on the paper. Synthetic Biologics, a clinical-stage company focused on targeting pathogen-specific diseases, has licensed the antibodies from UT Austin to eventually bring the product to market.
“In the developing world, an estimated 200,000 babies die a year, and that’s where we think we can have a really big impact,” Maynard said. “If we can get our antibodies to these high-risk infants, we could potentially prevent the infection from occurring in the first place.”
When an infant is infected with pertussis, a secreted toxin, called pertussis toxin, damages the immune system and causes the infant’s white blood cell count to rise to dangerous levels in the bloodstream — levels where the cells could block blood flow through the lungs.
Maynard’s two antibodies potently neutralize pertussis toxin and could be used individually or be developed as a combination therapeutic. The first binds to the toxin and prevents it from attaching to healthy cells; the second stops the toxin from reaching its target within a healthy cell.
By neutralizing pertussis toxin, the antibodies are anticipated to bolster immune function and rapidly reduce the white blood cell count.
“We believe the key to preventing death is reducing the white blood cell load, which becomes extremely elevated during infection,” Kaleko said. “If we can bring the count down or keep it low, the sick child may have a much better prognosis.”
When the team administered the antibodies before infection in mice, the treatment acted as a vaccine, giving passive immunity to pertussis. When administered after infection in nonhuman primates, the antibodies lowered the white blood cell counts, speeding recovery.
In animal models, the antibodies did not completely eradicate the pertussis bacteria, but they diminished the bacterial loads and kept symptoms at bay. The researchers think the treatment could be combined with antibiotics to eliminate the bacteria that cause the illness.
The team’s long-term plans are to advance an antibody product to human trials to evaluate its potential for two clinical applications. As a treatment, the therapeutic may be tested in critically ill infants with pertussis to potentially shorten the disease’s course, mitigate complications and diminish mortality. As a prophylactic, the therapeutic has the potential to provide antibody protection instantly to at-risk newborns in the developing world to protect them from pertussis for the first few months of life, the timeframe during which the infants are at greatest risk for severe disease but are too young to be immunized.
“We want to make sure that our research is really going to have impact,” Maynard said. “Most of the babies who get sick haven’t been immunized, so we hope to provide the immunity that they are lacking.”
The University of Texas at Austin is committed to transparency and disclosure of all potential conflicts of interest. The university investigator who led this research, Jennifer Maynard, has submitted required financial disclosure forms with the university. Maynard has received research funding for this project from Synthetic Biologics, a clinical-stage company that is a key collaborator and co-author, as well as the Welch Foundation and the Norman Hackerman Advanced Research Program. She has received funding for past projects from other corporate sponsors, including Cephalon and Pfizer, and from major national science funding agencies, including the National Institutes of Health, the Department of Defense and the National Science Foundation.Tags: antibodies, antibody treatments, CDC, chemical engineering, Cockrell School of Engineering, Inc., Jennifer Maynard, McKetta Department of Chemical Engineering, pertussis, prophylaxis, research, Science Translational Medicine, Synthetic Biologics, Texas ChE, The University of Texas at Austin, therapeutic drugs, treatments for whooping cough, UT Austin, whooping cough